Feb 26, 2020 6:30am EST ProMIS Neurosciences Initiates Natural History Study of Blood-Based Biomarkers in Alzheimer’s Disease
Feb 25, 2020 6:30am EST ProMIS Neurosciences Announces Gross Proceeds of $1,257,970 Related to the Exercise of Common Stock Warrants
Feb 11, 2020 6:30am EST ProMIS Neurosciences to Participate in Noble Capital Markets 16th Annual Investor Conference
Jan 29, 2020 6:30am EST ProMIS Neurosciences Data for Alzheimer’s Disease Program Targeting Tau Accepted for Presentation at Tau2020
Jan 15, 2020 6:30am EST ProMIS Neurosciences Appoints Dr. José Luis Molinuevo to its Scientific Advisory Board
Jan 09, 2020 6:30am EST ProMIS Neurosciences to present at Sachs 3rd Annual Neuroscience Innovation Forum
Jan 08, 2020 6:30am EST ProMIS Neurosciences issues Chairman’s Update detailing positive outlook for Alzheimer’s disease therapy, pipeline in 2020